NovImmune SA - Product Pipeline Review - Q4 2010

GlobalData, November 2010, Pages: 42

NovImmune SA – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “NovImmune SA - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- NovImmune SA - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of NovImmune SA human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of NovImmune SA with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the NovImmune SA’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate NovImmune SA’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of NovImmune SA in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the NovImmune SA’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with NovImmune SA.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of NovImmune SA and identify potential opportunities in those areas.

List of Tables
List of Figures
NovImmune SA Snapshot
NovImmune SA Overview
Key Information
Key Facts
NovImmune SA – Research and Development Overview
Key Therapeutic Areas
NovImmune SA – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
NovImmune SA – Pipeline Products Glance
NovImmune SA Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
NovImmune SA–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
NovImmune SA – Drug Profiles
NI-0401
Product Description
Mechanism of Action
R&D Progress
NI-0801
Product Description
Mechanism of Action
R&D Progress
NI-0501
Product Description
Mechanism of Action
R&D Progress
NI-0701
Product Description
Mechanism of Action
R&D Progress
NI-0101
Product Description
Mechanism of Action
R&D Progress
NI-1201
Product Description
Mechanism of Action
R&D Progress
NI-1401
Product Description
Mechanism of Action
R&D Progress
NovImmune SA – Pipeline Analysis
NovImmune SA – Pipeline Products by Therapeutic Class
NovImmune SA Pipeline Products By Target
NovImmune SA – Pipeline Products by Route of Administration
NovImmune SA – Pipeline Products by Molecule Type
NovImmune SA - Dormant Projects
NovImmune SA – Locations And Subsidiaries
Head Office
Recent Developments
Jul 13, 2009: NovImmune Successfully Completes NI-0801 Phase I Clinical Study
May 12, 2009: NovImmune Completes Equity Financing To Move Portfolio Forward And Reacquire Product Rights To NI-0501
May 12, 2009: NovImmune Completes Equity Financing To Move Portfolio Forward And Reacquire Product Rights To NI-0401 and NI-0501
Jun 26, 2006: NOVIMMUNE Initiates Phase I/IIa Trials Proof-Of-Concept Study With NI-0401
Jan 19, 2006: Medarex Announces NovImmune Filing Of Investigational New Drug Application For NI-0401
May 17, 2005: Serono And Novimmune To Collabrate In Development Of NI-0401 and NI-0501 For Autoimmune diseases
May 17, 2005: Serono And Novimmune To Collaborate In The Development Of Two Novel Treatments For Autoimmune Diseases
Financial Deals Landscape
NovImmune SA, Deals Volume Summary, 2004 to YTD 2010
NovImmune SA, Deals Summary By Region, 2004 to YTD 2010
NovImmune SA, Deals Summary, 2004 to YTD 2010
NovImmune SA Detailed Deal Summary
Venture Financing
NovImmune Raises $54.8 Million In Venture Financing
NovImmune Raises $46 Million In Series B Financing
Kalypsys Enters Into Collaboration With NovImmune
Serono Signs An Agreement With NovImmune
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Aerospace and Defense Industry - Global Strategic Business Report
• eLEARNING - Global Strategic Business Report
• How the Immune System Works. Includes Desktop Edition
• Charter Schools - Global Outlook
• Aerospace and Defence Industry - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• United States Battery Market for Military/Aerospace Applications